Department of Anesthesiology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, 266035, P.R. China.
Department of Anesthesiology, Qilu Hospital of Shandong University, Jinan, 250000, P.R. China.
BMC Anesthesiol. 2023 Dec 6;23(1):399. doi: 10.1186/s12871-023-02359-8.
The effects of intravenous glucocorticoids on postoperative delirium (POD) in adult patients undergoing major surgery remain controversial. Therefore, we conducted this meta-analysis to assess whether intravenous glucocorticoids can decrease POD incidence in the entire adult population undergoing major surgery and its association with patients age, type of surgery, and type of glucocorticoid.
We searched the relevant literature published before November 3, 2023, through Cochrane Library, PubMed, Embase, and Web of Science. The primary outcome was POD incidence. The risk ratio for the primary outcome was calculated using the Mantel-Haenszel method. The secondary outcomes included 30-day mortality, length of hospital stay, ICU duration, mechanical ventilation duration, and occurrence of glucocorticoid-related adverse effects (e.g., infection and hyperglycemia). This meta-analysis was registered in PROSPERO: CRD42022345997.
We included eight randomized controlled studies involving 8972 patients. For the entire adult population undergoing major surgery, intravenous glucocorticoids reduced the POD incidence (risk ratio = 0.704, 95% confidence interval, 0.519-0.955; P = 0.024). However, subgroups defined by type of surgery showed differential effects of glucocorticoids on POD. Intravenous glucocorticoids can not reduce POD incidence in adult patients undergoing cardiac surgery (risk ratio = 0.961, 95% confidence interval, 0.769-1.202; P = 0.728), with firm evidence from trial sequential analysis. However, in major non-cardiac surgery, perioperative intravenous glucocorticoid reduced the incidence of POD (risk ratio = 0.491, 95% confidence interval, 0.338-0.714; P < 0.001), which warrants further studies due to inconclusive evidence by trial sequence analysis. In addition, the use of glucocorticoids may reduce the mechanical ventilation time (weighted mean difference, -1.350; 95% confidence interval, -1.846 to -0.854; P < 0.001) and ICU duration (weighted mean difference = -7.866; 95% confidence interval, -15.620 to -0.112; P = 0.047).
For the entire adult population undergoing major surgery, glucocorticoids reduced the POD incidence. However, the effects of glucocorticoids on POD appear to vary according to the type of surgery. In patients receiving major non-cardiac surgery, glucocorticoid may be an attractive drug in the prevention of POD, and further studies are needed to draw a definitive conclusion. In cardiac surgery, intravenous glucocorticoids have no such effect.
静脉注射糖皮质激素对行大手术的成年患者术后谵妄(POD)的影响仍存在争议。因此,我们进行了这项荟萃分析,以评估静脉注射糖皮质激素是否能降低所有接受大手术的成年患者的 POD 发生率,以及其与患者年龄、手术类型和糖皮质激素类型的关系。
我们通过 Cochrane 图书馆、PubMed、Embase 和 Web of Science 检索了截至 2023 年 11 月 3 日之前发表的相关文献。主要结局是 POD 发生率。使用 Mantel-Haenszel 方法计算主要结局的风险比。次要结局包括 30 天死亡率、住院时间、重症监护病房持续时间、机械通气持续时间和糖皮质激素相关不良反应(如感染和高血糖)的发生。本荟萃分析已在 PROSPERO 注册:CRD42022345997。
我们纳入了八项涉及 8972 名患者的随机对照研究。对于所有接受大手术的成年患者,静脉注射糖皮质激素可降低 POD 发生率(风险比=0.704,95%置信区间,0.519-0.955;P=0.024)。然而,按手术类型划分的亚组显示糖皮质激素对 POD 的作用存在差异。静脉注射糖皮质激素不能降低接受心脏手术的成年患者的 POD 发生率(风险比=0.961,95%置信区间,0.769-1.202;P=0.728),这一点得到了试验序贯分析的有力证据支持。然而,在大非心脏手术中,围手术期静脉内使用糖皮质激素可降低 POD 的发生率(风险比=0.491,95%置信区间,0.338-0.714;P<0.001),由于试验序贯分析的证据不明确,这需要进一步研究。此外,糖皮质激素的使用可能会减少机械通气时间(加权均数差,-1.350;95%置信区间,-1.846 至-0.854;P<0.001)和重症监护病房持续时间(加权均数差=-7.866;95%置信区间,-15.620 至-0.112;P=0.047)。
对于所有接受大手术的成年患者,糖皮质激素可降低 POD 发生率。然而,糖皮质激素对 POD 的影响似乎因手术类型而异。在接受大非心脏手术的患者中,糖皮质激素可能是预防 POD 的一种有吸引力的药物,需要进一步研究以得出明确的结论。在心脏手术中,静脉内糖皮质激素没有这种作用。